# Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab

> **NCT03982992** · PHASE2 · WITHDRAWN · sponsor: **Ludwig-Maximilians - University of Munich**

## Conditions studied

- B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation
- B-Cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia in Remission
- Acute Lymphoblastic Leukemia, Adult

## Interventions

- **DRUG:** Blinatumomab in combination with donor lymphocyte infusion

## Key facts

- **NCT ID:** NCT03982992
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-01
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of potential study subjects due to a change of standard of care treatment outside of clinical trials.
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982992, "Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03982992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*